Search Results
A phase 1b/2 study targeting apoptotic and signaling pathways in T-acute lymphoblastic leukemia
T-acute lymphoblastic leukemia (T-ALL) is an aggressive leukemia with limited treatment options after first-line chemotherapy. Our preclinical work in animal models of T-ALL demonstrated the activity of a novel-novel combination treatment strategy, which includes LP-118 (activator of suicide pathways within leukemic cells) and tyrosine kinase inhibitors (inhibiting growth-promoting LCK and ACK1 signaling pathways).Meet an LLS Advocacy Volunteer: Amanda Steffy
Amanda Steffy of Pasadena, Calif. is one of The Leukemia & Lymphoma Society’s most passionate policy advocates. She frequently travels to Washington, D.C. to speak with lawmakers about the importance of high-quality, affordable healthcare for cancer patients. In California, where she works as an instrument systems engineer for NASA JPL, she recruits and teaches others to do the same.
This May, Steffy joins LLS for its first-ever virtual advocacy event. In this interview, Steffy explains how she first became involved in advocacy and why she’s so passionate about the work.
DEVELOPING RELATIONSHIPS ON CAPITOL HILL
As the voice for all blood cancer patients, The Leukemia & Lymphoma Society (LLS) establishes and grows meaningful relationships with policymakers
The Leukemia & Lymphoma Society is committed to removing barriers to care for blood cancer patients, and works with federal and state legislators to advocate for policies to ensure patients have access to quality, affordable care and treatments they need.
Here’s an inside look at how we cultivate these key connections:
211Astatine-CD123 Radioimmunotherapy for Cancer (Stem) Cell-Directed Treatment of Acute Leukemia
Because acute leukemias are very sensitive to radiation, radioisotopes are ideal payloads to arm antibodies against these difficult-to-cure, aggressive blood cancers. Here, we will develop fully human anti-CD123 antibodies carrying the highly potent alpha-emitter astatine-211 (211At) as a new therapy for acute leukemia.
Forbes Women’s Summit 2019: LLS’s Chief Medical Officer Joins Women In Leading the Way
More than 400 women from diverse backgrounds in business, entertainment, fashion, media, healthcare, science and finance came together this week to inspire and encourage one another at the 2019 Forbes Women’s Summit at Pier 60 Chelsea Piers in New York City.
The attendees engaged in animated discussions about how women are changing the world while still fighting to overcome obstacles they face in the workforce and on the world stage.